Solésence Q2 Revenue Drops 25% to $15.3M, Swings to Net Loss
SLSN sits 50% above its 52-week low of $0.613 on light trading volume (0.3× avg).
Summary
Solésence reported Q2 2026 revenue of $15.3 million, down 25% from $20.4 million a year ago, and swung to a net loss of $158,000 from net income of $3.2 million. Gross margin slipped to 31% from 32%. The company attributed the decline to a one-time revenue boost in the prior-year period from a major product launch and initial inventory pipeline fill. This follows the 10-Q filed today that disclosed restated financials due to inventory costing errors and a material weakness in internal controls. The company will host a conference call at 5:00 p.m. ET today to discuss results.
At the time of this announcement, SLSN was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.4M. The 52-week trading range was $0.61 to $4.55. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.